JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 5
DOI: 10.33266/1024-6177-2022-67-5-52-58
L.I. Moskvicheva, S.V. Medvedev, L.V. Bolotina
POSSIBILITIES OF MODERN RADIATION THERAPY
IN PATIENTS WITH PANCREATIC CANCER
P.A. Hertsen Moscow Oncology Research Institute, Moscow, Russia
Contact person: Liudmila I. Moskvicheva, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Introduction: Until now, malignant neoplasms of the pancreas remain a very important oncological problem, which is determined by the long subclinical course of the disease, the primary diagnosis of most tumors already at advanced stages, as well as the pronounced effect of this pathology on the functional status and overall quality of life of patients. No more than a quarter of patients with pancreatic cancer can be operated on. The remaining significant part of patients receive palliative anticancer treatment and/or symptomatic therapy.
Purpose: The purpose of this work is to analyze the possibilities of modern methods of radiation therapy in patients with pancreatic cancer based on the analysis of scientific sources of the Internet resource National Center for Biotechnology Information.
Sections: This article describes the role of preoperative chemoradiotherapy using 3D-conformal techniques in patients with localized and borderline resectable pancreatic cancer, the effectiveness of chemoradiotherapy as an adjuvant component, and the possibilities of this method in patients with locally advanced disease. The advantages of modern radiotherapy regimens are demonstrated: with modulated intensity or volume intensity modulation by arches, stereotaxic technique, proton and adaptive MR-guided radiation therapy. The international experience of brachytherapy in patients with pancreatic cancer was analyzed.
Conclusion: Modern methods of radiotherapy are widely used in clinical practice for the treatment of patients with adenogenic pancreatic cancer. The implementation of various options for radiation or chemoradiation therapy can significantly increase the survival rates of patients with localized, borderline resectable and locally advanced process, the frequency of achieving local tumor control and its duration, as well as improve the quality of life of patients by reducing the severity of abdominal pain syndrome. Constant improvement in the technique of radiation treatment contributes to a natural decrease in the frequency of early and late radiation reactions.
Keywords: pancreatic cancer, radiation therapy, brachytherapy, proton beam therapy, intensity modulated radiation therapy, stereotactic body radiotherapy, adaptive magnetic resonance image-guided radiation therapy
For citation: Moskvicheva LI, Medvedev SV, Bolotina LV. Possibilities of Modern Radiation Therapy in Patients with Pancreatic Cancer. Medical Radiology and Radiation Safety. 2022;67(5):52–58. (In Russian). DOI: 10.33266/1024-6177-2022-67-5-52-58
References
1. Состояние онкологической помощи населению России в 2019 году / Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. М: МНИОИ им. П.А.Герцена, 2020. 239 с. [The State of Oncological Care to the Population of Russia in 2019. Ed. Kaprin A.D., Starinskiy V.V., Shakhzadova A.O. Moscow Publ., 2020. 239 p. (In Russ.)].
2. McGuigan A., Kelly P., Turkington R.C., Jones C., Coleman H.G., McCain R.S. Pancreatic Cancer: A Review of Clinical Diagnosis, Epidemiology, Treatment and Outcomes. World J. Gastroenterol. 2018;24;43:4846-4861. DOI: 10.3748/wjg.v24.i43.4846.
3. Москвичева Л.И., Петров Л.О., Сидоров Д.В. Возможности современных методов абляции при нерезектабельном местно-распространенном раке поджелудочной железы // Исследования и практика в медицине. 2018. Т.5, № 2 С. 86-99. [Moskvicheva L.I., Petrov L.O., Sidorov D.V. The Possibilities of Modern Methods of Ablation in Non-Resectable Locally Advanced Pancreatic Cancer. Issledovaniya i Praktika v Meditsine = Research’n Practical Medicine Journal. 2018;5;2:86-99 (In Russ.)]. DOI: 10.17709/2409-2231-2018-5-2-10.
4. Москвичева Л.И., Болотина Л.В. Возможности химиотерапии у больных местно-распространенным и метастатическим аденогенным раком поджелудочной железы // Исследования и практика в медицине. 2020. Т.7, № 4. С. 118-134. [Moskvicheva L.I., Bolotina L.V. Possibilities of Chemotherapy in Patients with Locally Advanced and Metastatic Adenogenic Pancreatic Cancer. Issledovaniya i Praktika v Meditsine = Research’n Practical Medicine Journal. 2020;7;4:118-134
(In Russ.)]. DOI: 10.17709/2409-2231-2020-7-4-10.
5. Robin T.P., Goodman K.A. Radiation Therapy in the Management of Pancreatic Adenocarcinoma: Review of Current Evidence and Future Opportunities. Chin. Clin. Oncol. 2017;6;3:28. DOI: 10.21037/cco.2017.06.12.
6. Hong T.S., Ryan D.P., Borger D.R., Blaszkowsky L.S., Yeap B.Y., Ancukiewicz M., et al. A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation with Proton Beam Therapy and Capecitabine Followed by Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2014;89;4:830-838. DOI: 10.1016/j.ijrobp.2014.03.034.
7. Hall W.A., Goodman K.A. Radiation Therapy for Pancreatic Adenocarcinoma, a Treatment Option that must Be Considered in the Management of a Devastating Malignancy. Radiat. Oncol. 2019;14;1:114. DOI: 10.1186/s13014–019–1277–1.
8. Golcher H., Brunner T.B., Witzigmann H., Marti L., Bechstein W.O., Bruns C., et al. Neoadjuvant Chemoradiation Therapy with Gemcitabine/Cisplatin and Surgery Versus Immediate Surgery in Resectable Pancreatic Cancer: Results of the First Prospective Randomized Phase II Trial. Strahlenther Onkol. 2015;191;1:7-16. DOI: 10.1007/s00066–014–0737–7.
9. Versteijne E., Suker M., Groothuis K., Akkermans-Vogelaar J.M., Besselink M.G., Bonsing B.A., et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J. Clin. Oncol. 2020;38;16:1763-1773. DOI: 10.1200/JCO.19.02274.
10. Hsu C.C., Herman J.M., Corsini M.M., Winter J.M., Callister M.D., Haddock M.G., et al. Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic Collaborative Study. Ann. Surg. Oncol. 2010;17;4:981-990. DOI: 10.1245/s10434–009–0743–7.
11. Hammel P., Huguet F., van Laethem J.L., Goldstein D., Glimelius B., Artru P., et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315;17:1844-1853. DOI: 10.1001/jama.2016.4324.
12. Медведев С.В., Ткачев С.И. Рак поджелудочной железы // Терапевтическая радиология. Национальное руководство. Гл. 15 / Под ред. ак. Каприна А.Д., Мардынского Ю.С. М.: ГЭОТАР-Медиа, 2018. С. 155-159. [Medvedev S.V., Tkachev S.I. Pancreatic Cancer. Terapevticheskaya Radiologiya. Natsionalnoye Rukovodstvo = Therapeutic Radiology. National Leadership. Ch. 15. Ed. Kaprin A.D., Mardynskiy Yu.S. Moscow, GEOTAR-Media Publ., 2018. P. 155-159 (In Russ.)].
13. Krishnan S., Chadha A.S., Suh Y., Chen H.C., Rao A., Das P., et al. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 2016;94;4:755-765. DOI: 10.1016/j.ijrobp.2015.12.003.
14. Ткачев С.И., Медведев С.В., Знаткова Я.Р., Романов Д.С., и др. Возможности стереотаксической лучевой терапии при паллиативном лечении больных раком поджелудочной железы // Вопросы онкологии. 2015, Т.61, № 1. С. 121–124. [Tkachev S.I., Medvedev S.V., Znatkova Ya.R., Romanov D.S., et al. The Possibilities of Stereotactic Radiotherapy in Palliative Treatment of Patients with Pancreatic Cancer. Voprosy Onkologii = Problems in Oncology. 2015;61;1:121–124 (In Russ.)].
15. Reyngold M., Parikh P., Crane C.H. Ablative Radiation Therapy for Locally Advanced Pancreatic Cancer: Techniques and Results. Radiat. Oncol. 2019;14;1:95. DOI: 10.1186/s13014–019–1309–x.
16. Zhong J., Patel K., Switchenko J., Cassidy R.J., Hall W.A., Gillespie T., et al. Outcomes for Patients with Locally Advanced Pancreatic Adenocarcinoma Treated with Stereotactic Body Radiation Therapy Versus Conventionally Fractionated Radiation. Cancer. 2017;15;123;18:3486-3493. DOI: 10.1002/cncr.30706.
17. Dohopolski M.J., Glaser S.M., Vargo J.A., Balasubramani G.K., Beriwal S. Stereotactic Body Radiotherapy for Locally-Advanced Unresectable Pancreatic Cancer-Patterns of Care and Overall Survival. J. Gastrointest Oncol. 2017;8;5:766-777. DOI: 10.21037/jgo.2017.08.04.
18. Jung J., Yoon S.M., Park J.H., Seo D.W., Lee S.S., Kim M.H., et al. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer. PLoS One. 2019;14;4:e0214970. DOI: 10.1371/journal.pone.0214970.
19. Zhong J., Switchenko J., Behera M., Kooby D., Maithel S.K., McDonald M.W., et al. Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. Ann Surg. Oncol. 2018;25;4:1026-1033. DOI: 10.1245/s10434–017–6322–4.
20. Herman J.M., Chang D.T., Goodman K.A., Dholakia A.S., Raman S.P., Hacker-Prietz A., et al. Phase 2 Multi-Institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma. Cancer. 2015;121;7:1128-1137. DOI: 10.1002/cncr.29161.
21. Nichols R.C.Jr., George T.J., Zaiden R.A.Jr, Awad Z.T., Asbun H.J., Huh S., et al. Proton Therapy with Concomitant Capecitabine for Pancreatic and Ampullary Cancers is Associated with a Low Incidence of Gastrointestinal Toxicity. Acta. Oncol. 2013;52;3:498-505. DOI: 10.3109/0284186X.2012.762997.
22. Thompson R.F., Mayekar S.U., Zhai H., Both S., Apisarnthanarax S., Metz J.M., et al. A Dosimetric Comparison of Proton and Photon Therapy in Unresectable Cancers of the Head of Pancreas. Med. Phys. 2014;41;8:081711. DOI: 10.1118/1.4887797.
23. Hiroshima Y., Fukumitsu N., Saito T., Numajiri H., Murofushi K.N., Ohnishi K., et al. Concurrent Chemoradiotherapy Using Proton Beams for Unresectable Locally Advanced Pancreatic Cancer. Radiother Oncol. 2019;136:37-43. DOI: 10.1016/j.radonc.2019.03.012.
24. Henke L., Kashani R., Yang D., Zhao T., Green O., Olsen L., et al. Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages. Int. J. Radiat. Oncol. Biol. Phys. 2016;96;5:1078-1086. DOI: 10.1016/j.ijrobp.2016.08.036.
25. Bohoudi O., Bruynzeel A.M.E., Senan S., Cuijpers J.P., Slotman B.J., Lagerwaard F.J., Palacios M.A. Fast and Robust Online Adaptive Planning in Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) for Pancreatic Cancer. Radiother Oncol. 2017;125;3:439-444. DOI: 10.1016/j.radonc.2017.07.028.
26. Rudra S., Jiang N., Rosenberg S.A., Olsen J.R., Roach M.C., Wan L., et al. Using Adaptive Magnetic Resonance Image-Guided Radiation Therapy for Treatment of Inoperable Pancreatic Cancer. Cancer Med. 2019;8;5:2123-2132. DOI: 10.1002/cam4.2100.
27. Jia S.N., Wen F.X., Gong T.T., Li X., Wang H.J., Sun Y.M., Yang Z.C. A Review on the Efficacy and Safety of Iodine-125 Seed Implantation in Unresectable Pancreatic Cancers. Int. J. Radiat. Biol. 2020;96;3:383-389. DOI: 10.1080/09553002.2020.1704300.
28. Sun X., Lu Z., Wu Y., Min M., Bi Y., Shen W., et al. An Endoscopic Ultrasonography-Guided Interstitial Brachytherapy Based Special Treatment-Planning System for Unresectable Pancreatic Cancer. Oncotarget. 2017;8;45:79099-79110. DOI: 10.18632/oncotarget.15763.
29. Zhang K., Liao A., Jiang P., Jiang Y., Ji Z. Expert Consensus Workshop Report: Guideline for Three-Dimensional Printing Template-Assisted Computed Tomography-Guided 125i Seeds Interstitial Implantation Brachytherapy. J. Cancer Res. Ther. 2017;13;4:607-612. DOI: 10.4103/jcrt.JCRT_412_17.
30. Guo J.H., Hu X.K., Teng G.J. Radioactive Seed Implantation Therapy Technology: Problems and Development. Natl. Med. J. China. 2017;97:1444–1445.
31. Gai B., Zhang F. Chinese Expert Consensus on Radioactive 125I Seeds Interstitial Implantation Brachytherapy For Pancreatic Cancer. J. Cancer Res. Ther. 2018;14;7:1455-1462. DOI: 10.4103/jcrt.JCRT_96_18.
32. Folkert M.R., Gottumukkala S., Nguyen N.T., Taggar A., Sur R.K. Review of Brachytherapy Complications - Upper Gastrointestinal Tract. Brachytherapy. 2021;20;5:1005-1013. DOI: 10.1016/j.brachy.2020.11.010.
33. Han Q., Deng M., Lv Y., Dai G. Survival of Patients with Advanced Pancreatic Cancer after Iodine125 Seeds Implantation Brachytherapy: A Meta-Analysis. Medicine (Baltimore). 2017;96;5:e5719. DOI: 10.1097/MD.0000000000005719.
34. Chi Z., Chen L., Huang J., Jiang N., Zheng Q., Huang N., Yang W. A Novel Combination of Percutaneous Stenting with Iodine-125 Seed Implantation and Chemotherapy for the Treatment of Pancreatic Head Cancer with Obstructive Jaundice. Brachytherapy. 2021;20;1:218-225. DOI: 10.1016/j.brachy.2020.09.009.
35. Bhutani M.S., Cazacu I.M., Luzuriaga Chavez A.A., Singh B.S., Wong F.C.L., et al. Novel EUS-Guided Brachytherapy Treatment of Pancreatic Cancer with Phosphorus-32 Microparticles: First United States Experience. VideoGIE. 2019;4;5:223-225. DOI: 10.1016/j.vgie.2019.02.009.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.06.2022. Accepted for publication: 25.08.2022.